Reaction Biology
Global contract research organization (CRO) founded in 2001 that provides drug discovery and development services across biochemical, cellular, biophysical, and in vivo models. Operates multiple campuses in North America and Europe and offers regulated GMP/GLP bioanalytical testing, broad target and cell-line libraries, biomarker discovery, and data-mining capabilities to support early discovery through clinical support.
Industries
Nr. of Employees
medium (51-250)
Reaction Biology
Malvern, Pennsylvania, United States
Patents
Products
Miniaturized radiometric kinase profiling platform
A miniaturized radiometric assay workflow for kinase activity and selectivity profiling that reduces reagent use and radioactive waste compared with traditional filter-binding formats.
Large-panel cell and target profiling datasets
Curated profiling datasets combining cellular activity across large cell-line panels and multi-omic annotations for target discovery and ADC target selection.
Miniaturized radiometric kinase profiling platform
A miniaturized radiometric assay workflow for kinase activity and selectivity profiling that reduces reagent use and radioactive waste compared with traditional filter-binding formats.
Large-panel cell and target profiling datasets
Curated profiling datasets combining cellular activity across large cell-line panels and multi-omic annotations for target discovery and ADC target selection.
Services
Functional enzymatic and protein assays for target characterization and inhibitor testing.
Cellular model development, phenotypic screens and mechanism-of-action assays in 2D and 3D formats.
Binding kinetics and thermodynamics testing using biophysical methods to support lead optimization.
Regulated bioanalytical assays and potency/batch-release testing for large molecules under GMP/GLP.
Exploratory and GLP toxicology studies, immunotoxicity evaluation and safety profiling to support preclinical development.
Preclinical efficacy models including syngeneic, orthotopic and humanized models for pharmacology and translational studies.
Functional enzymatic and protein assays for target characterization and inhibitor testing.
Cellular model development, phenotypic screens and mechanism-of-action assays in 2D and 3D formats.
Binding kinetics and thermodynamics testing using biophysical methods to support lead optimization.
Regulated bioanalytical assays and potency/batch-release testing for large molecules under GMP/GLP.
Exploratory and GLP toxicology studies, immunotoxicity evaluation and safety profiling to support preclinical development.
Preclinical efficacy models including syngeneic, orthotopic and humanized models for pharmacology and translational studies.
Expertise Areas
- Kinase profiling and inhibitor selectivity
- Preclinical pharmacology and in vivo efficacy models
- Biochemical and biophysical assay development
- Cell-based and phenotypic screening (2D/3D)
Key Technologies
- Large kinase assay panels
- Miniaturized radiometric enzymatic assays
- High-throughput screening platforms
- Cell co-culture and 3D spheroid/organoid models
News & Updates
Conference attendance in Stockholm, Sweden.
Conference attendance in Seville, Spain.
Conference attendance in Boston, MA, USA.
Company interview and 25th anniversary overview detailing technology origins, expansion into assays and in vivo models, and strategic roadmap.
Discussion of immune-profiling assays and how early in vitro immunology supports diverse therapeutic areas and translational strategy.
Acquired Bioassay GmbH and subsidiary to add GMP/GLP-accredited bioanalytical and peptide-synthesis capabilities and expand large-molecule testing.
Conference attendance in Stockholm, Sweden.
Conference attendance in Seville, Spain.
Conference attendance in Boston, MA, USA.
Company interview and 25th anniversary overview detailing technology origins, expansion into assays and in vivo models, and strategic roadmap.
Discussion of immune-profiling assays and how early in vitro immunology supports diverse therapeutic areas and translational strategy.
Acquired Bioassay GmbH and subsidiary to add GMP/GLP-accredited bioanalytical and peptide-synthesis capabilities and expand large-molecule testing.